1380098-47-4

Upstream product

• 100-51-6 benzyl alcohol 
• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 1296176-75-4 2,6-dibenzyloxyisonicotinic acid 

Downstream Products

• 1296176-82-3 2-{2,6-dibenzyloxyisonicotinoyloxy}-5-chloro-4-hydroxypyridine 
• 1296176-78-7 4-{2,6-dibenzyloxyisonicotinoyloxy}-5-chloro-2-hydroxypyridine 
• 1296176-84-5 2,4-di{2,6-dibenzyloxyisonicotinoyloxy}-5-chloropyridine 
• 1296176-95-8 3-{3-[4-(2,6-dibenzyloxyisonicotinoyloxy)-5-chloro-2-pyridyloxycarbonyl]benzoyl}-1-ethoxymethyl-5-fluorouracil 
• 1296176-98-1 3-{3-[4-(2,6-dihydroxyisonicotinoyloxy)-5-chloro-2-pyridyloxycarbonyl]benzoyl}-1-ethoxymethyl-5-fluorouracil 
• 1296177-10-0 3-{3-[4-(2,6-diisobutyryloxyisonicotinoyloxy)-5-chloro-2-pyridyloxycarbonyl]benzoyl}-1-ethoxymethyl-5-fluorouracil 

Relevant academic research and scientific papers

NOVEL 5-FLUOROURACIL DERIVATIVE

The present invention provides a novel antimetabolic anticancer agent that has an excellent balance between antitumor effect and toxicity. Specifically, the present invention provides a medicament containing, as an active ingredient, a 5-fluorouracil derivative represented by Formula (I) or a salt thereof: wherein R1 represents a hydrogen atom or a protecting group of a hydroxy group, R2 represents a lower alkoxy-lower alkyl group or a tetrahydrofuranyl group, X represents a carbon atom or a nitrogen atom, and Y represents a halogen atom or a cyano group.